iloprost inhalation

Phase 2Small molecule

Johnson & Johnson

iloprost inhalation is one of 135 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Pulmonary HypertensionPhase 2/Phase 3

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

iloprost inhalation

Johnson & Johnson

Phase 2

1 2

Formoterol Fumarate

AstraZeneca

Preclinical

11 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Calciferol

Alnylam Pharmaceuticals

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 6

Coumadin

AAbbott

Preclinical

1 7

Zoloft

VViatris Specialty LLC

Preclinical

1 8

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

—9

Versed

CConrado Roberto Hoffmann Filho

Antibiotic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Hypertension1 trial

Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis

Unknown status·IInterstitial Lung Disease Study Group, Korea·Phase 2/3·NCT00439543·15 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

Completed·UUniversity of Oklahoma·N/A·NCT00561223·10 enrolled

Pulmonary Arterial Hypertension1 trial

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00453414

Idiopathic Pulmonary Fibrosis1 trial

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00109681·50 enrolled

One-lung Ventilation1 trial

Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation

Completed·YYonsei University·N/A·NCT04583046·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for iloprost inhalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iloprost inhalation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iloprost inhalation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

iloprost inhalation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Hypertension1 trial

Chronic Obstructive Pulmonary Disease1 trial

Pulmonary Arterial Hypertension1 trial

Idiopathic Pulmonary Fibrosis1 trial

One-lung Ventilation1 trial

References

Drug Info

Quick Facts

Related News